A nationwide nonprofit advancing cancer prevention, treatment, and care.
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with previously treated or ineligible metastatic pancreatic cancer. Clinical trials have shown median survival extended to about 13.2 months versus roughly 6.7 months with chemotherapy. The drug will be available in the US with a roughly $39,800 monthly list price and expanded-access programmes have already treated thousands.
GLP-1 medications are being increasingly prescribed off-label to children aged 8–11 in the US, despite no FDA approval for under-12s. A NYU Langone study shows a dramatic rise in June 2026, while experts warn about long-term effects and the broader obesity crisis.
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Pope Leo XIV has undergone surgery at Rome's Gemelli Hospital to remove the lower lobe of his right lung after doctors found a small, localized nodule. Surgeons have confirmed lung adenocarcinoma; doctors have said postoperative blood tests and a chest X‑ray are within expected ranges and the pope has begun physiotherapy and walking in his room.
The American Cancer Society has updated guidelines on PSA testing for prostate cancer. Average-risk men should begin screening at 50 with tests every two years until 69. Higher-risk groups, including Black men and those with a family history, should start at 45 with annual tests. The update emphasizes repeat testing to confirm high results and the possible use of MRI or biomarkers before biopsy. Continued screening after 70 is decision-based.